Genomics and epigenomics: New promises of personalized medicine for cancer patients

Briefings in Functional Genomics

Volumn 12, Issue 5, 2013, Pages 411-421

  Schweiger, Michal Ruth ^a   Barmeyer, Christian ^b   Timmermann, Bernd ^c  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Max Planck Society in Berlin   (Germany)

Author keywords

Epigenomics; Genomics; High throughput sequencing; Individualized therapy; Personalized medicine

Indexed keywords

5 METHYLCYTOSINE; 5 METHYLCYTOSINE ANTIBODY; ANTIBODY; BINDING PROTEIN; DNA FRAGMENT; ENDONUCLEASE; FLUORESCENT DYE; METHYL BINDING PROTEIN; MICRORNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

AFFINITY ENRICHMENT SEQUENCING; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RESEARCH; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME BANDING PATTERN; COPY NUMBER VARIATION; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTIONAL GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME PROJECT; IMMUNOPRECIPITATION; INDEL MUTATION; LAB ON A CHIP; LABORATORY DEVICE; METHYLATION DEPENDENT IMMUNOPRECIPITATION; MOLECULAR CLONING; NANOPORE; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE H RAS; PERSONALIZED MEDICINE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; RESTRICTION MAPPING; TUMOR GENE; TUMOR SUPPRESSOR GENE;

EPIGENOMICS; GENOMICS; HIGH-THROUGHPUT SEQUENCING; INDIVIDUALIZED THERAPY; PERSONALIZED MEDICINE;

EPIGENOMICS; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84884515523     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elt024     Document Type: Article

References (68)

1. Timmermann B, Kerick M, Roehr C, et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010;5:e15661.
2. Schweiger MR, Hussong M, Rohr C, et al. Genomics and epigenomics of colorectal cancer. Wiley Interdiscip Rev Syst BiolMed 2013;5:205-19.
3. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. NEnglJMed 2009;361:1058-66.
4. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. JClin OncolOffJAmSocClin Oncol 2010;28: 5219-28.
5. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
6. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the BCR gene and its role in the Ph' translocation. Nature 1985;315:758-61.
7. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17.
8. Ball MP, Thakuria JV, Zaranek AW, et al. A public resource facilitating clinical use of genomes. Proc Natl Acad Sci USA 2012;109:11920-27.
9. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65.
10. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genom Human Genet 2008;9:387-402.
11. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437:376-80.
12. Albert TJ, Molla MN, Muzny DM, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods 2007;4:903-5.
13. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009;27:182-9.
14. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad SciUSA 2009;106:19096-101.
15. Hodges E, Xuan Z, Balija V, et al. Genome-wide in situ exon capture for selective resequencing. Nat Genet 2007;39: 1522-7.
16. Porreca GJ, Zhang K, Li JB, etal. Multiplex amplification of large sets of human exons. NatMethods 2007;4:931-6.
17. Clarke J, Wu HC, Jayasinghe L, et al. Continuous base identification for single-molecule nanopore DNA sequencing. NatNanotechnol 2009;4:265-70.
18. Greenleaf WJ, Block SM. Single-molecule, motion-based DNA sequencing using RNA polymerase. Science 2006;313: 801.
19. Sugiyama S, Yoshino T, Tsukamoto K, et al. Application of scanning probe microscopy to genetic analysis. Jpn J App Phys 2006;45:2305-9.
20. Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum Mol Genet 2010;19: R227-40.
21. Murray IA, Clark TA, Morgan RD, et al. The methylomes of six bacteria. Nucleic Acids Res 2012;40:11450-62.
22. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3.
23. Le Tourneau C, Kamal M, Tredan O, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted Oncol 2012;7: 253-65.
24. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010;11:191-203.
25. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
26. de Wit E, de Laat W. A decade of 3C technologies: insights into nuclear organization. Genes Dev 2012;26:11-24.
27. Segal E, Widom J. From DNA sequence to transcriptional behaviour: a quantitative approach. Nat Rev Genet 2009;10: 443-56.
28. Farnham PJ. Insights from genomic profiling of transcription factors. Nat Rev Genet 2009;10:605-16.
29. Rando OJ, Chang HY. Genome-wide views of chromatin structure. AnnuRev Biochem 2009;78:245-71.
30. Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 1998;20:116-7.
31. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-40.
32. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
33. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983;11:6883-94.
34. Borno ST, Fischer A, Kerick M, et al. Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discov 2012; 2(11):1024-35.
35. Banerjee HN, Verma M. Epigenetic mechanisms in cancer. BiomarkMed 2009;3:397-410.
36. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet 2008;24: 231-7.
37. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010;11:191-203.
38. Lister R, Ecker JR. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res 2009;19: 959-66.
39. Pomraning KR, Smith KM, Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 2009;47:142-50.
40. Rakyan VK, Down TA, Thorne NP, et al. An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). GenomeRes 2008;18:1518-29.
41. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009;27:361-8.
42. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853-62.
43. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006;38:149-53.
44. Cross SH, Charlton JA, Nan X, et al. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994;6:236-44.
45. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated- CpG islands in cancer. Lab Invest JTechMethods Pathol 2005;85:1172-80.
46. Down TA, Rakyan VK, Turner DJ, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol 2008;26:779-85.
47. Brunner AL, Johnson DS, Kim SW, et al. Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver. Genome Res 2009;19:1044-56.
48. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999;59: 2307-12.
49. Oda M, Glass JL, Thompson RF, et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res 2009;37:3829-39.
50. Berman BP, Weisenberger DJ, Laird PW. Locking in on the human methylome. Nat Biotechnol 2009;27:341-2.
51. Carr IM, Valleley EM, Cordery SF, et al. Sequence analysis and editing for bisulphite genomic sequencing projects. Nucleic Acids Res 2007;35:e79.
52. Korshunova Y, Maloney RK, Lakey N, et al. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res 2008;18:19-29. 53. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res 1980;8:4777-90.
53. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res 1980;8:4777-90
54. Hodges E, Smith AD, Kendall J, et al. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res 2009;19: 1593-1605.
55. Deng J, Shoemaker R, Xie B, etal. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009;27:353-60.
56. Li JB, Gao Y, Aach J, et al. Multiplex padlock targeted sequencing reveals human hypermutable CpG variations. Genome Res 2009;19:1606-15.
57. Meissner A, Gnirke A, Bell GW, et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res 2005;33: 5868-77.
58. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008;454:766-70.
59. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad SciUSA 1992;89:1827-31.
60. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-40.
61. Warnecke PM, Stirzaker C, Melki JR, et al. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res 1997; 25:4422-6.
62. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-85.
63. Weng L, Zhang L, Peng Y, et al. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 2013;14:315-24.
64. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13: 679-92.
65. Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res 2012;22:2101-8.
66. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. SciTranslMed 2011;3:111ra121.
67. De Matteis G, Graudenzi A, Antoniotti M. A review of spatial computational models for multi-cellular systems, with regard to intestinal crypts and colorectal cancer development. JMath Biol 2013;66:1409-62.
68. Wierling C, Kuhn A, Hache H, et al. Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. Mutat Res 2012;746: 163-70.